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Summary Immunoglobulin E (IgE) is a key mediator of the inflammatory reactions
that are central to the pathogenesis of allergic diseases such as asthma and rhinitis.
The recognition of the importance of IgE in allergic disease led to the development
of omalizumab, a humanized monoclonal anti-IgE antibody that binds free
circulating IgE and prevents the interaction between IgE and high-affinity (FceRI)
and low-affinity (FceRII) IgE receptors on inflammatory cells. By removing free IgE,
omalizumab also markedly downregulates the expression of high-affinity receptorsee front matter & 2006
med.2005.10.004
5160 2301; fax: +49 89 5
ess: dennis.nowak@meon basophils, mast cells and dendritic cells. Several studies have shown that
omalizumab effectively reduces the risk of exacerbations and hospitalization and
improves symptom control, lung function and quality of life in patients with severe
persistent allergic asthma. Importantly, omalizumab has been shown to be effective
in patients with poorly controlled severe persistent allergic asthma, a group of
patients with few effective additional treatment options. In addition, omalizumab
has been shown to provide effective relief from the symptoms of allergic rhinitis
(including patients with concomitant asthma). Patients with uncontrolled severe
persistent allergic asthma are a challenging and difficult-to-treat population for
whom omalizumab might represent an important new treatment option. In addition,
omalizumab may provide a means to address comorbid allergic disease in patients
with asthma. Further investigation is also warranted to explore potential
applications of omalizumab in occupational asthma.
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Immunoglobulin E (IgE) has been known to be a key
mediator of allergic reactions for more than 30
years and plays a central role in allergic responses
to allergens in patients with asthma and rhinitis.1,2
IgE is produced by B cells after sensitization to an
allergen3 and has a short half-life.4 Despite low
serum concentrations, IgE is immunologically highly
active due to the large number of high-affinity IgE
receptors on mast cells and basophils.3 In addition,
IgE up-regulates receptors on several cell types,
including basophils and mast cells.4,5 The binding of
IgE to the receptors on these cells results in the
formation of cross links between the allergen and
the IgE molecule and initiates the inflammatory
cascade through release of a variety of mediators,
including histamine, leukotrienes (LT), and plate-
let-activating factor.6
Current evidence suggests that the majority of
asthma has an allergic basis7,8 and that IgE is
central to the initiation of both allergic and non-
allergic asthma.9–11 Indeed, population studies
indicate that almost all asthma is associated with
elevated IgE levels.12 In addition, IgE also plays a
central role in many cases of occupational asthma13
as well as in a variety of allergic conditions,
including rhinitis.14
The central role of IgE in allergic disease created
interest in developing treatments based on anti-IgE
antibodies. In particular, it was hoped that new
treatments based on anti-IgE approaches mightTable 1 Percentage of patients who were not totally co
Stratum Patients no
Fluticasone
1. Corticosteroid naı¨ve 22
2. p500 mg/day BDP or equivalent 25
3. 4500 to p1000mg/day BDP 38
BDP ¼ beclometasone dipropionate.provide a means to improve control of allergic
asthma and better meet the goals set out in the
Global Initiative for Asthma (GINA) guidelines.15
According to the GINA guidelines, treatment should
be adjusted using a stepwise approach based on
asthma severity. Treatment for mild intermittent
asthma (step 1) is based on use of rescue
bronchodilators as needed, with increasing doses
of inhaled corticosteroids (ICS) used to control mild
(step 2), moderate (step 3), and severe (step 4)
persistent asthma. Patients with moderate persis-
tent asthma should also receive a long-acting b2-
agonists (LABA) or alternatively sustained-release
theophylline, an oral b2-agonists or a LT modifier.
For patients with severe persistent asthma, high-
dose ICS and LABA are recommended with addi-
tional agents added if required. The Gaining
Optimal Asthma Control (GOAL) study showed that
many patients fail to achieve control of asthma
despite treatment with corticosteroids (flutica-
sone) or combination salmeterol/fluticasone ther-
apy.16 Although the GOAL study showed that using
combined salmeterol and fluticasone increased the
percentage of patients achieving control of their
asthma, many patients remained inadequately
controlled, especially in the group with the most
severe asthma where 38% and 53% of patients
remained inadequately controlled despite treat-
ment with salmeterol/fluticasone and fluticasone,
respectively (Table 1).
The association between an increased risk of
death and factors characteristic of more severentrolled or well controlled in the GOAL study.16
t totally controlled or well controlled (%)
/salmeterol Fluticasone
30
40
53
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Asthma management with omalizumab 1909disease has been evident for many years. For
example, Rea et al.17 found that previous hospital
admission for asthma increases the risk of death 16-
fold. More recent studies indicate that a history of
severe asthma is associated with a greater than 6-
fold increase in the risk of death within 3 years of
discharge from hospital.18 The high risk of morbid-
ity and mortality means that achieving the best
possible control of severe asthma should be a high
priority. Unfortunately, as noted in the GINA
guidelines, complete control of severe asthma is
often not possible with currently available treat-
ments15 and, therefore, an urgent need exists for
improved options to manage severe persistent
asthma, especially in patients with inadequate
control using currently available treatment regi-
mens.
The role of IgE in allergic diseases other than
asthma also raises the possibility that anti-IgE
approaches could have broader applications than
conventional asthma medications. In particular,
strong evidence shows that allergic asthma and
rhinitis represent different facets of a common
inflammatory process affecting both the upper and
lower respiratory tract,3 but that the central role
of IgE in both conditions means that effective
treatments targeting inflammation mediated by IgE
might be clinically useful in both conditions,
especially in light of the high prevalence of
comorbid asthma and rhinitis. Findings from epide-
miological studies suggest that between 60% and
80% of patients with asthma have rhinitis, while
20–40% of patients with rhinitis have asthma.19–21
In addition, a variety of substances can trigger
occupational asthma and there is evidence of
elevated IgE levels in large numbers of people
exposed to numerous agents found in the work-
place.22–25 There may therefore be potential
applications of anti-IgE therapies, such as omalizu-
mab, in the management of occupational asthma
associated with elevated IgE.
Omalizumab, currently the only anti-IgE agent
available for the treatment of allergic asthma, has
been investigated in several clinical studies of
allergic rhinitis. This article therefore evaluates
the evidence from clinical trials of omalizumab,
with a focus on the treatment of severe persistent
asthma, and discusses potential applications in
clinical practice.Mechanism of action of omalizumab
Omalizumab is a humanized monoclonal anti-IgE
antibody that binds to the high-affinity and low-affinity receptor regions of the IgE molecule (Ce3
domain) thereby preventing free IgE from inter-
acting with IgE receptors.26 By binding to the
allergen-specific region of the IgE molecule, but
not cell-bound IgE, omalizumab inhibits allergen-
induced responses without causing receptor cross-
linking, which could lead to anaphylaxis.
Reductions in free IgE alone would not likely be
sufficient to block IgE-mediated inflammatory
reactions because the high density of receptors on
effector cells require at least a 99% reduction in
levels in the circulation.27 However, as well as
reducing circulating IgE levels by approximately
99%, omalizumab down-regulates receptor expres-
sion on basophils.28–30 A study of the reversibility
of this down-regulation of receptor expression
suggested that it was a consequence of the
reductions in serum IgE caused by omalizumab.30
It therefore appears that omalizumab acts by
directly reducing free IgE levels, which in
turn leads to reduced receptor expression on
effector cells. Recent studies have also re-
ported that omalizumab down-regulates high-affi-
nity IgE receptor (FceRI) expression on dendritic
cells.31–33
The combined effect of reduced free IgE levels
and down-regulation of receptor expression could
theoretically result in potent inhibition of IgE-
mediated inflammatory reactions. Consistent with
this hypothesis, omalizumab reduces both the early
and the late asthmatic responses,34,35 with sig-
nificant improvements in forced expiratory volume
in 1 s (FEV1) after allergen challenge during both
phases (Fig. 1),35 as well as reducing the number of
IgE+ and FceRI+cells in the bronchial submucosal
and epithelial tissues of patients with asthma.36
Omalizumab reduces numbers of IgE-positive cells
and local and systemic IgE production in patients
with allergic rhinitis37,38 as well as eosinophilia in
patients with allergic asthma.36 Given recent
evidence that the prevalence of high-affinity IgE
receptor expression is approximately 3-fold higher
in cases of fatal asthma than in mild intermittent
asthma,39 reducing numbers of IgE+ and FceRI+
cells36 may be particularly important in reducing
mortality due to asthma. The effects of omalizu-
mab on eosinophil numbers may also be important
in light of the relationship between eosinophilia,
airway inflammation, asthma severity, and the risk
of exacerbations.40,41 In addition, as FceRI receptor
expression on dendritic cells is increased in
patients with allergic asthma,42 the inhibitory
effect of omalizumab on dendritic cell FceRI
expression suggests that omalizumab may alter
allergen presentation, a fundamental step in the
allergic response.
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Figure 1 Forced expiratory volume in 1 s (FEV1) as a
percentage of baseline in the first hour after allergen
challenge (early phase response) and from 2 to 7 h after
allergen challenge (late phase response) in the placebo
group (A) (n ¼ 9) and omalizumab group (B) (n ¼ 9) at
baseline (open squares) and at the end of treatment
(closed squares). Reproduced with permission.35
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Patients who fail to achieve adequate control of
severe persistent asthma despite receiving LABAs
and ICS in line with the GINA guidelines are at a
high risk of morbidity and mortality and have
limited treatment options. The high risk of morbid-
ity and mortality in severe asthma, combined with
the limited treatment options available for patients
with inadequately controlled severe asthma, pro-
vided a strong rationale for investigating the
efficacy of omalizumab in this patient population.
The INvestigatioN of Omalizumab in seVere Asthma
TrEatment (INNOVATE) study exclusively enrolled
patients with inadequately controlled severe per-
sistent allergic asthma despite GINA 2002 step 4
therapy.43 In addition, the efficacy of omalizumab
was also investigated in 3 other double-blind,
placebo-controlled studies44–48 and an open-label
study in patients with allergic asthma49 as well as a
study of patients with concomitant asthma and
persistent allergic rhinitis.50 Although these studies
were initiated prior to GINA 2002 guidelines,
subsequent analysis found that 490% of patientsin each study met GINA 2002 criteria for severe
persistent asthma.51Clinical efficacy
INNOVATE was a double-blind, multicentre, paral-
lel-group study in which patients were randomized
to receive omalizumab (n ¼ 209) or placebo
(n ¼ 210) for 28 weeks.43 At the end of this 28-
week period, patients receiving omalizumab had a
26% reduction in the rate of clinically significant
asthma exacerbations (defined as a worsening of
asthma symptoms requiring treatment with sys-
temic corticosteroids and adjusted for baseline
exacerbation history) compared with placebo (0.68
versus 0.91, P ¼ 0:042) (Table 2; Fig. 2). Without
adjustment, a similar magnitude of effect was seen
(19% reduction), but this did not attain statistical
significance (0.74 versus 0.92, P ¼ 0:153). Consis-
tent with this finding, omalizumab also reduced
severe exacerbations (defined as peak expiratory
flow [PEF] or FEV1o60% of personal best, requiring
systemic corticosteroids) by 50% (0.24 versus 0.48,
P ¼ 0:002) (Fig. 2) and emergency visits by 44%
(0.24 versus 0.43, P ¼ 0:038). The reduction in
asthma exacerbations and hospital admissions in
patients receiving omalizumab was also reflected
in significantly greater improvements in morning
PEF (P ¼ 0:042), FEV1 percent predicted values
(P ¼ 0:043), and total asthma symptom scores
(P ¼ 0:039) compared with placebo recipients.
The effectiveness of omalizumab was rated as
excellent or good by 60.5% of investigators and
64.3% of patients in the INNOVATE study.
The findings of the INNOVATE study were con-
sistent with the results of an open-label study.49
During the 52 weeks of this study, patients
receiving omalizumab (n ¼ 206) in addition to best
standard care had approximately half as many
asthma-related deterioration incidents as patients
receiving best standard care alone (n ¼ 106)
(4.92 versus 9.76 per patient year, respectively)
(Table 2). Treatment with omalizumab also led to a
significant reduction in the number of clinically
significant asthma exacerbations (1.12 versus 2.86
per patient year, respectively) and a significant
increase in the percentage of patients requiring
rescue medication less often than once a week
(41.4% versus 20.7%, respectively). A recent sub-
group analysis of patients with severe persistent
asthma enrolled in this open-label study showed
that the addition of omalizumab to best standard
care resulted in a 59% reduction in the annual
rate of asthma exacerbations, compared with best
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Figure 2 Effect of omalizumab treatment on the rate of
(A) clinically significant asthma exacerbations (adjusted
for baseline exacerbation history) and (B) severe exacer-
bations during the 28-week treatment period in the
primary intent-to-treat population. Values are means and
95% confidence intervals. Reproduced with permission.43
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line in patients with severe asthma (Busse/Lanier study).
Reproduced with permission.47
D. Nowak1912standard care alone (1.24 versus 3.00, respectively,
Po0:001).52
Several other studies have provided additional
evidence of the efficacy of omalizumab in patients
with severe persistent allergic asthma. Reductions
in the incidence of exacerbations in patients
receiving omalizumab were reported in 3 rando-
mized, placebo-controlled studies45,46,48 (Table 2).
The reductions in exacerbations were also accom-
panied by significant reductions in hospitalization
and a significantly greater reduction in the ICS
requirements in patients receiving omalizumab
compared with those taking placebo (Fig. 3). In a
meta-analysis of data obtained in the three
studies,45,46,48 omalizumab was particularly effec-
tive in patients who were at high risk of serious
asthma-related morbidity and mortality.53 In an-
other analysis of data from 2 of the 3 studies45,48
factors indicative of more severe asthma (history of
emergency treatment and high-dose ICS) were
predictive of a response to omalizumab.54 In
addition, 2 of the studies included 24-week exten-
sion periods beyond the original 28–30-week
studies and demonstrated that the benefits were
sustained44,47 (Table 2). Omalizumab was highlyrated in subjective evaluations of effectiveness,
with 60–70% of patients and investigators describ-
ing treatment with omalizumab as excellent or
good, compared with approximately 40% for place-
bo.45,55
In a pooled analysis of the studies of omalizumab,
which included the studies described above, Bous-
quet et al. found that omalizumab significantly
reduced the annualized asthma exacerbation rate
by 38% (Po0:0001) and the emergency visit rate by
47% (Po0:0001) (Table 3), compared with the
control group.51 It is notable that 93% of patients
included in this pooled analysis met GINA 2002
criteria for severe persistent asthma.Quality of life
Reducing the incidence of exacerbations and
improving symptom control and lung function
would be expected to improve quality of life
(QoL) for patients with severe persistent asthma.
The studies of omalizumab utilized asthma-specific
QoL questionnaires (AQLQ).56,57 These question-
naires are designed to reflect the areas that
patients consider most important: symptoms clas-
sically associated with asthma; responses to envir-
onmental stimuli; limitation of activities; and
emotional dysfunction.
In the INNOVATE trial, more patients receiving
omalizumab reported a clinically meaningful im-
provement of at least 0.5 points on the Juniper
AQLQ than patients receiving placebo (60.8% versus
47.8%, respectively).43 The improvements in QoL
seen in the INNOVATE study occurred across all 4
domains of the AQLQ (activity limitation, emotions,
symptoms, exposure to environmental stimuli)
(Fig. 4). A more detailed QoL analysis from another
study of omalizumab provided further evidence of
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Table 3 Emergency visits in a pooled analysis of clinical trials of omalizumab in patients with predominately
severe persistent asthma. Reproduced with permission.51
Rate per year Treatment
difference
Ratio (95% CI) P-value
Omalizumab Control
Total emergency visits 0.332 0.623 0.291 0.533 (0.401, 0.709) o0.0001
Hospital admissions 0.030 0.062 0.032 0.489 (0.246, 0.972) 0.041
Emergency room visits 0.026 0.066 0.040 0.397 (0.192, 0.820) 0.013
Unscheduled doctor visits 0.252 0.443 0.191 0.568 (0.417, 0.774) 0.0003
Asthma management with omalizumab 1913the beneficial effects of omalizumab on QoL.55 At
weeks 28 and 52, patients receiving omalizumab
had higher AQLQ scores for all 4 domains and for
the total AQLQ score. Similarly, an analysis of QoL
from another study showed that omalizumab was
associated with significant improvements in all 4
domains of the AQLQ.58 A pooled analysis of the
QoL outcomes in these 2 studies confirmed that
omalizumab resulted in significantly greater im-
provements in AQLQ in all 4 domains and for the
total score, at the end of both the steroid-stable
and steroid-reduction phases of the trials. In a
recent analysis of QoL from 6 clinical trials, change
from baseline in AQLQ score was significantly
greater for omalizumab compared with control in
all studies.59Omalizumab in allergic rhinitis
Several studies investigated the efficacy of omali-
zumab in patients with seasonal or perennial
allergic rhinitis. In 2 studies of patients with
seasonal allergic rhinitis, treatment with omalizu-
mab resulted in significant reductions in daily nasal
symptom severity scores.60,61 These improvements
in nasal symptom scores were associated withreduced IgE levels and led to decreases in rescue
antihistamine use and improved QoL scores. Similar
reductions in nasal symptom scores have been
reported in patients with perennial allergic rhinitis
(Fig. 5).62
This evidence of efficacy in allergic rhinitis,
combined with the evidence of effective asthma
control described above, indicates that omalizu-
mab would be expected to provide a means to
control both conditions in patients with comorbid-
ity. Confirmation of the efficacy of omalizumab for
the treatment of comorbid allergic respiratory
disease was provided by a study of patients with
concomitant allergic asthma and rhinitis.50 In this
study, patients receiving omalizumab had fewer
asthma exacerbations than placebo recipients
(Table 2) in addition to lower asthma and rhinitis
scores on the Wasserfallen scale.
In a study of 221 children with seasonal allergic
rhinitis to both birch and grass pollen, omalizumab
provided additional symptomatic benefit when
given concomitantly with specific immunotherapy
(SIT) to birch or pollen, compared with placebo plus
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from this study, who were receiving omalizumab or
placebo plus SIT to grass or birch pollen, ex vivo
allergen stimulation of circulating leukocytes
showed a decrease in LT release (LTC4, LTD4,
LTE4), independent of type of allergen SIT used,
in children receiving omalizumab (P ¼ 0:001 versus
SIT alone).64 Thus, children receiving omalizumab
plus birch SIT had reduced leukocyte mediator
release when stimulated with grass (and birch)
allergen, and vice versa. In this study, SIT alone had
no effect on LT release.Omalizumab in occupational asthma
According to the GINA guidelines, allergens and
occupational sensitizers are the most important
causes of asthma and can cause the initial
sensitization of the airways that leads to develop-
ment of asthma, as well as precipitating subse-
quent exacerbations and ongoing symptoms.15
Several studies have indicated that asthma can be
caused by occupational exposure to a huge variety
of allergens or chemicals, including cow, horse, and
laboratory animal dander, flour, mites, platinum
salts, biological enzymes and organic chemi-
cals.13,65–67
IgE levels are elevated in many people exposed
to known causes of occupational asthma. For
example, a population-based survey in Italy showed
that people who reported occupational exposure to
dusts, chemicals, or gases had significantly higher
serum IgE levels than those reporting no exposure
(43 versus 35 kU/l, respectively, P ¼ 0:008).25 Simi-
lar increases in IgE levels have been reported in
people exposed to a variety of occupational
sensitizers, including dusts and gases,24 rose oil,22
and enzymes used in the detergent industry.23
At present, there is little direct evidence of the
efficacy of omalizumab in other asthmatic popula-
tions, such as those with occupational asthma.
However, the importance of IgE in the pathophy-
siology of occupational asthma, combined with
evidence of efficacy in latex allergy,68 indicates
that omalizumab warrants further investigation as
a potential treatment for occupational asthma.
This is particularly relevant for patients who are
unable to avoid allergen exposure in their place of
work.Omalizumab in other allergic conditions
Several studies have shown that omalizumab is
effective in a variety of conditions associated withelevated IgE levels and exposure to a variety of
substances, including latex, and peanuts. In health-
care workers with latex allergies, treatment with
omalizumab was associated with reductions in
conjunctival allergen challenge scores at 8 and 16
weeks.68 Others have reported that omalizumab
may be effective in treating IgE-mediated severe
eye allergies.69 In addition, patients with peanut
allergy who received another anti-IgE antibody,
TNX-901, had large increases in the threshold of
sensitivity to oral challenge with peanut (from 178
to 2805mg).70 This would be equivalent to an
increase in the threshold from approximately half a
peanut to almost 9 peanuts, and suggests that anti-
IgE agents might be expected to provide useful
protection from accidental peanut ingestion.
The efficacy of anti-IgE in a variety of conditions
related to IgE and sensitizers such as pollen, latex,
and peanuts, indicates that treatment might be
beneficial in patients with allergic conditions caused
or exacerbated by similar sensitizers. Further
clinical trials are needed to explore this potentially
useful clinical application of omalizumab.Safety and tolerability
The safety and tolerability of omalizumab has been
extensively evaluated in more than 7500 adult
patients with asthma, allergic rhinitis, and related
conditions.71 The nature and frequency of adverse
events (AEs) followed a similar pattern in the active
and control treatment groups. The most frequent
AEs (regardless of relationship to treatment)
occurred with similar frequencies in the omalizu-
mab and placebo groups, and included nasophar-
yngitis (14.4% versus 15.9%, respectively), upper
respiratory tract infection (15.7% in both groups),
headache (15.5% versus 15.6%, respectively) and
sinusitis (10.1% versus 12.0%, respectively). Serious
AEs were infrequent in both the omalizumab (4.2%)
and control groups (3.8%).
There was no evidence of increased risk of
immune-complex mediated or other hypersensitiv-
ity reactions, infections or bleeding-related AEs in
omalizumab-treated patients. None of the omali-
zumab-treated patients developed measurable
anti-omalizumab antibodies. Clinical evidence does
not suggest that omalizumab treatment is asso-
ciated with an increased risk of malignancy.72Clinical applications of omalizumab
Inadequate control of asthma places a substantial
burden on patients and healthcare providers and
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GINA guidelines specify that patients with severe
asthma should receive ICS at doses of at least
1000 mg/day in combination with LABAs.15 If these
agents fail to achieve control of asthma, the
guidelines recommend using additional agents,
such as theophylline, LT modifiers, oral b2-agonists,
or oral corticosteroids. However, the guidelines
note that despite treatment, it may not be possible
to achieve complete control of severe persistent
asthma. At present there is little that can be done
to improve asthma control in patients who fail to
achieve control despite GINA step 4 therapy. The
proven efficacy of omalizumab in patients with
inadequately controlled severe persistent asthma43
and the limitations of current options provide a
clear rationale for the use of omalizumab as an
add-on therapy in this patient population.
There is also a strong rationale for considering
the use of omalizumab in the broader population of
patients with severe persistent asthma, given the
strong evidence of reductions in the incidence of
exacerbations, improved asthma symptom scores
and pulmonary function tests, and reduced rescue
medication use seen in clinical trials.45,48,50 The
large reductions in annualized asthma exacerbation
rate and emergency visits in a combined analysis of
the clinical trials of omalizumab suggest that
treatment of severe persistent asthma with omali-
zumab will result in significant reductions in
morbidity in this population of patients.51
The evidence of efficacy in other allergic condi-
tions, especially allergic rhinitis, suggests that
omalizumab may also have the potential to address
comorbid allergic disease in patients with asthma.
The central role of IgE in both allergic asthma and
rhinitis, combined with evidence of efficacy in both
conditions and in a study of comorbid patients,50
indicates that omalizumab might be useful in the
management of allergic disease throughout the
respiratory tract.Table 4 Summary of the characteristics of omalizumab.
Binds free circulating IgE and prevents the interaction be
(FceRII) IgE receptors on inflammatory cells, which also res
on mast cells, basophils and dendritic cells
Reduces eosinophilia in the airways of patients with aller
Reduces exacerbation rates and emergency visit/hospitali
asthma
Improves quality of life in patients with severe persistent
Improves symptoms in patients with allergic rhinitis (seas
allergic asthma and allergic rhinitisConclusions
Allergic asthma causes considerable morbidity and
mortality and places a large burden on patients and
healthcare providers. Despite treatment with LA-
BAs and high daily doses of ICS, many patients have
severe persistent asthma that is inadequately
controlled and there is little that can be done to
improve asthma control in these patients.
The central role of IgE in allergic inflammatory
processes presented an attractive target for novel
therapies such as omalizumab (Table 4) for patients
with allergic disease and particularly for those with
severe persistent allergic asthma. Omalizumab is
an anti-IgE antibody that significantly reduces
serum IgE levels and down-regulates IgE receptor
expression in vitro and in vivo. Clinical studies in
patients with asthma have provided convincing
evidence that omalizumab is effective in patients
with severe asthma and that it may be particularly
useful in patients whose asthma is inadequately
controlled despite GINA step 4 therapy. Indeed,
anti-IgE was included as an add-on therapy to high-
dose ICS and LABA in the most recent update of the
GINA guidelines in 2004.
There is now a large body of evidence demon-
strating the central role of IgE in a wide variety of
allergic conditions, including diseases of the upper
airway (rhinitis) and lower airway (asthma), as well
as in occupational asthma. This evidence provides a
rationale for considering the potential application
of omalizumab to a broader range of allergic
disease. Consistent with this rationale, omalizumab
has been shown to be effective in patients with
allergic rhinitis and in a study of occupational latex
allergy. There is therefore strong evidence to
support the efficacy of omalizumab in allergic
rhinitis and especially in patients with concomitant
asthma and rhinitis. Further studies are warranted
to explore the benefits of omalizumab in occupa-
tional asthma.tween IgE and high-affinity (FceRI) and low-affinity
ults in downregulation of the high-affinity IgE receptors
gic asthma
zation rates in patients with severe persistent allergic
allergic asthma
onal and perennial) and in patients with concomitant
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